Anti Amyloid Leqembi denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for anti amyloid leqembi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Leqembi as "Not FDA-Approved" — and Why This Denial Is Directly Contestable

Leqembi (lecanemab) received traditional FDA approval for early Alzheimer's disease. A denial stating the drug is not FDA-approved is factually incorrect given the current regulatory record. This type of denial is among the most straightforwardly reversible in the appeals process because the factual predicate of the denial — unapproved status — can be disproven with publicly available documentation.

## Why This Denial Happens

This denial typically arises from one of three causes: Aetna's internal formulary or claims database has not been updated to reflect the traditional approval; the claim was coded in a way that did not trigger recognition of the approved drug; or Aetna is applying a coverage policy written before the traditional approval was granted and has not revised it. In all three cases, the error is administrative, not clinical, and is correctable on appeal.

## Federal Appeal Rights

• Internal appeal (ACA §2719 / ERISA §503): Submit a formal written appeal within the timeframe on the denial notice. The full-and-fair review standard obligates Aetna to engage with the documentary evidence of FDA approval you submit.
• Expedited appeal: If your neurologist certifies that delay poses a serious health risk, Aetna must respond within 72 hours.
• External review: If Aetna upholds the denial after internal review, request independent external review within approximately four months of the final denial. An IRO presented with an FDA approval letter upholding a "not FDA-approved" denial has clear grounds to reverse. IRO decisions are binding on Aetna.
• State insurance commissioner: If you believe Aetna is maintaining a policy that conflicts with the regulatory record, a complaint to your state insurance commissioner is an additional parallel remedy.

## Documentation to Gather

1. FDA approval letter and prescribing label — Download the current official label and the FDA approval action letter from the FDA website. These are your primary exhibits. Highlight the approval date, the approved indication, and the approval type (traditional). 2. Aetna's coverage policy — Request the specific policy Aetna cited in the denial. Note the policy's last-revised date and compare it to the FDA approval date. 3. Diagnosis and eligibility records — Clinical notes confirming early symptomatic Alzheimer's disease and amyloid confirmation, showing your case falls within the approved indication. 4. Prescriber letter — A letter from the neurologist confirming that the drug prescribed is Leqembi, that it is FDA-approved, and that the patient meets the approved indication.

## Criteria-Mapping Structure for Your Appeal

| Denial Basis | Aetna's Claim | Documented Fact | |---|---|---| | Approval status | Not FDA-approved | FDA traditional approval letter + label | | Coverage policy currency | Per Aetna's policy | Policy revision date vs. FDA approval date | | Indication match | N/A (admin error) | Diagnosis records + prescriber letter |

Open your appeal letter by citing the FDA approval date and attaching the approval letter as Exhibit A. Ask Aetna to identify the specific regulatory basis for characterizing an FDA-approved drug as unapproved.